This Viewpoint discusses a 2018 Centers for Medicare & Medicaid Services national coverage determination on next-generation sequencing tests for patients with advanced cancer and suggests ways to ensure appropriate and equitable access to testing, resource efficiency, and improvement in patient and societal outcomes.